Precigen Inc (FRA:I5X)
€ 0.8505 0.017 (2.04%) Market Cap: 264.54 Mil Enterprise Value: 252.32 Mil PE Ratio: 0 PB Ratio: 5.71 GF Score: 45/100

Precigen Inc R&D Update Virtual Event Transcript

Dec 15, 2020 / 04:00PM GMT
Release Date Price: €6 (-17.24%)
Operator

Good day and welcome to the Precigen R&D Update and Clinical Development Call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to Steven Harasym, Head of Investor Relations. Please go ahead, sir.

Steven Harasym
Precigen, Inc. - Head of IR

Thank you, Chuck. This is a very exciting time at Precigen, and I would like to extend a special thanks to everyone joining us today for an update on our clinical programs.

Next slide, please. Before we begin, I would like to remind you that, during today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by our looking statements. Please read the safe harbor statement contained in this presentation as well as the risk factors contained in Precigen's most recent SEC filings for a more complete discussion of these risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot